Prevention of Mouse Lung Tumors by Combinations of Chemopreventive Agents using Concurrent and Sequential Administration

• Published in: Anticancer research Vol. 31; no. 10; pp. 3279 - 3284
• Main Authors: CASTO, Bruce C, PEREIRA, Michael A
• Format: Journal Article
• Language: English
• Published: Attiki International Institute of Anticancer Research 01.10.2011
• Subjects: Animals; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Body Weight - drug effects; Budesonide - pharmacology; Budesonide - therapeutic use; Chemoprevention; Female; Hydroxamic Acids - pharmacology; Hydroxamic Acids - therapeutic use; Lung Neoplasms - drug therapy; Lung Neoplasms - prevention & control; Medical sciences; Mice; Pneumology; Tetrahydronaphthalenes - pharmacology; Tetrahydronaphthalenes - therapeutic use; Tumors; Tumors of the respiratory system and mediastinum; Lung disease; Animal model; Chemoprophylaxis; mouse model; Respiratory disease; Lung cancer; Concurrent; Rodentia; Malignant tumor; Prevention; Vertebrata; Chemotherapy; Mammalia; Treatment; Cancerology; chemoprevention; Mouse; Sequential; Animal; Bronchus disease; Combined treatment; Cancer
• ISSN: 0250-7005; 1791-7530

Concurrent and sequential administration of combinations of budesonide, bexarotene, suberoylanilide hydroxamic acid (SAHA) and atorvastatin were evaluated in A/J mice for prevention of lung tumors initiated by 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanol, NNK). Individual drugs and their combinations were administered for 26 weeks after NNK initiation. For sequential administration, budesonide was given for 21 weeks followed by a second drug. Alone, budesonide, bexarotene, and SAHA caused a significant decrease in total and large tumors at 21 and 26 weeks. Concurrent treatment with budesonide and bexarotene or SAHA caused a significantly greater decrease in total tumors and large tumors than either drug administered alone. Sequential administration of all combinations (except budesonide/atorvastatin) gave a significant reduction in total and large tumors. Budesonide followed by SAHA and SAHA with atorvastatin yielded a greater reduction in large tumors. Combinations of drugs demonstrated a greater efficacy in preventing mouse lung tumors than did the individual agents.